Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
-
+
- Abstract
Loading... -
+
JCSE 01.25 - Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC
11:30 - 11:30 | Presenter: Xu-Chao Zhang | Author(s): Z. Liang, Y. Chen, H. Zhang, W. Gang, Y. Lu, Z. Liang, Ying Cheng, Y. Hu, Jie Wang, J. Ying, W. Liu, Yi-Long Wu
- Abstract
Loading...
-
+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P1.01-002 - TP53 Mutations Predict for Poor Survival in ALK Rearrangement Lung Adenocarcinoma Patients Treated with Crizotinib
09:30 - 09:30 | Presenter: Gang Chen | Author(s): W. Wang, Chunwei Xu, Y. Chen, Wu Zhuang, G. Lin, X. Chen, B. Wu, Y. Huang, Rongrong Chen, Y. Guan, X. Yi, Meiyu Fang, T.F. Lv, Yong Song
- Abstract
Loading...
-
+
P1.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
-
+
P1.03-050 - Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial
09:30 - 09:30 | Presenter: David S Ettinger | Author(s): Oscar Arrieta, N.A. Karaseva, Gee-Chen Chang, A. Rittmeyer, Y. Huang, R. Cheng, R. Varea, H. Ostojic, G. Mi, K.B. Winfree, E. Alexandris, F.W. Chan-Diehl, Frederico Cappuzzo
- Abstract
Loading...
-
+
P1.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
-
+
P1.07-037 - Testing the Positive and Negative Immune Checkpoint on PBMCs of Patients from Initiatory to Terminative Treatment of Anti PD-1 Antibody
09:30 - 09:30 | Presenter: Wushuang Du | Author(s): Y. Hu
- Abstract
Loading...
-
+
P1.14 - Radiotherapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
-
+
- Abstract
Loading...
-
+
MA 06 - Lung Cancer Biology I
- 15:45 - 17:30
- 10/16/2017
- Location: Room 501
- Type: Mini Oral
- Track: Biology/Pathology
- Moderators:N. Motoi, Keith M Kerr
-
+
- Abstract
Loading...
-
+
P2.01 - Advanced NSCLC
- 09:00 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P2.01-035 - Phase II Study: Weekly Docetaxel as First Line Chemotherapy for Elderly Patients with Squamous-Cell Non-Small-Cell Lung Cancer
09:00 - 09:00 | Presenter: Kyung Ho Kang | Author(s): Sung Yong Lee, J.H. Choi, S.M. Chung, J.Y. Oh, Y.S. Lee, K.H. Min, G.Y. Hur, J.J. Shim, H.K. Lee
- Abstract
Loading...
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P2.04-001 - BALTIC: A Phase 2, Open-Label Study of Novel Combinations of Immunotherapies or DDR Inhibitors in Platinum-Refractory ED-SCLC
09:30 - 09:30 | Presenter: Ihor Vynnychenko | Author(s): H. Jiang, Y. Huang, P.A. Dennis, J. Von Pawel
- Abstract
Loading... -
+
P2.04-002 - CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
09:30 - 09:30 | Presenter: Luis Paz-Ares | Author(s): H. Jiang, Y. Huang, P.A. Dennis
- Abstract
Loading... -
+
P2.04-003 - Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) Non–Small-Cell Lung Cancer Who Progressed on Crizotinib
09:30 - 09:30 | Presenter: Li Zhang | Author(s): Junling Li, W. Zhong, Y. Hu, X. Liu, Z. Wang, Y. Zhao, J. Feng, J. Zhou, Y. Zhang, Yun Fan, G. Wu, F. Tan, L. Ding
- Abstract
Loading...
-
+
MA 11 - Emerging Diagnostic/Biomarkers in NSCLC
- 11:00 - 12:30
- 10/17/2017
- Location: Room 313 + 314
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:M.I. Abdul Wahid, Martin Reck
-
+
MA 11.03 - Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)
11:10 - 11:15 | Presenter: Jie Wang | Author(s): Ying Cheng, Yi-Long Wu, T. An, H. Gao, K. Wang, Qing Zhou, Y. Hu, Yong Song, C. Ding, F. Peng, L. Liang, Y. Hu, C. Huang, Caicun Zhou, Y. Shi, Li Zhang, X. Ye, Y. Sun
- Abstract
Loading...
-
+
OA 09 - EGFR TKI Resistance
- 11:00 - 12:30
- 10/17/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:Thanyanan Reungwetwattana, Lecia V Sequist
-
+
OA 09.02 - Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms
11:10 - 11:20 | Presenter: Geoffrey R. Oxnard | Author(s): Y. Hu, K.F. Mileham, P. Tracy, N. Feeney, L.M. Sholl, C.P. Paweletz, K.S. Thress, Pasi A Jänne
- Abstract
Loading...